特立帕肽日剂量与周剂量治疗药物相关性颌骨坏死的比较效果初步研究
本研究纳入13例骨质疏松合并II-III期药物相关性颌骨坏死(MRONJ)患者,随机分为每周56.5μg与每日20μg特立帕肽(TPTD)组治疗6个月,比较临床分期与骨代谢指标变化。结果显示全体12例患者及每日组MRONJ分期显著改善,而每周组无显著改善。
要点
- 每日特立帕肽20μg治疗6个月可显著改善骨质疏松患者MRONJ分期。
- 每周特立帕肽56.5μg治疗6个月未显示MRONJ分期的显著改善。
- 全体患者中5例每日组和3例每周组达到部分或完全缓解。
核心结论
- 6个月特立帕肽治疗使全体患者及每日组的MRONJ分期较基线显著改善。
- 每周组MRONJ分期未见显著改善,每日组可见显著改善。
研究设计与样本
- 随机对照初步研究,纳入13例骨质疏松合并II-III期MRONJ患者。
- 每日组接受20μg特立帕肽注射每日一次,每周组接受56.5μg每周一次,疗程6个月。
- 两组均接受常规治疗及必要的强化抗生素治疗。
主要发现
- 每日组5例、每周组3例达到部分缓解或完全缓解。
- 全体12例患者MRONJ分期从基线至治疗6个月显著改善(p=0.008)。
- 每日组MRONJ分期显著改善(p=0.01),每周组无显著改善。
关键数值与推荐
- 每日组:特立帕肽20μg每日注射一次,持续6个月。
- 每周组:特立帕肽56.5μg每周注射一次,持续6个月。
- MRONJ分期改善在全体患者中p=0.008,每日组p=0.01。
临床怎么用
- 对于骨质疏松合并II-III期MRONJ患者,每日特立帕肽方案可能改善颌骨坏死分期。
- 每周特立帕肽方案在本研究中未显示显著分期改善,选择方案时需考虑给药频率差异。
局限性
- 本研究为初步研究,样本量小(每日组和每周组各6例完成)。
- 原文未报告盲法、随访时长及骨代谢指标的详细组间比较结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We studied the effectiveness of teriparatide (TPTD) for treating medication-related osteonecrosis of the jaw (MRONJ) in patients with osteoporosis and examined differences in the clinical outcomes following daily versus weekly TPTD. The outcomes were significantly improved in the entire patient series and the daily group. PURPOSE: Teriparatide (TPTD) treatment for Stage II-III medication-related osteonecrosis of the jaw (MRONJ) in osteoporotic patients has yielded promising results in uncontrolled studies. The daily administration and the weekly administration of TPTD have been reported to improve outcomes in MRONJ. Herein, we sought to identify differences in the clinical outcomes of MRONJ patients treated with daily TPTD versus weekly TPTD. METHODS: We enrolled 13 patients and randomly assigned them to receive either of two treatments: 1×/week 56.5-μg TPTD injection for 6 months (weekly group; n = 6 patients after 1 dropout), or 20-μg TPTD injection daily for 6 months (daily group; n = 6 patients). Patients in both groups received conventional therapy plus intensive antibiotic therapy as necessary. We compared the changes in the patients' clinical stage of MRONJ, bone metabolism, percentage of bone formation, and bone turnover markers between the weekly and daily groups. RESULTS: TPTD treatment with MRONJ led to partial remission or complete remission in 5 daily-group patients and 3 weekly-group patients. The MRONJ stage was significantly improved from baseline to 6 months of treatment in the entire series of 12 patients (p = 0.008); the weekly group did not show significant improvement, but the daily group did (p = 0.01). CONCLUSIONS: This study provides the first comparison of clinical outcomes between MRONJ patients who received daily or weekly TPTD injections. Six months of treatment with TPTD realized a significant improvement of MRONJ stage in both the entire patient series and the daily group.
引用
- Ohbayashi Y, Iwasaki A, Nakai F, et al. A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporos Int. 2019. PMID: 31768589. doi:10.1007/s00198-019-05199-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。